1. Narahara, Haruna, Sakai, Eiko, Yamaguchi, Yu, Yoshida, Noriaki, Tsukuba, Takayuki. 2018. Actin binding LIM 1 (abLIM1) negatively controls osteoclastogenesis by regulating cell migration and fusion. In Journal of cellular physiology, 234, 486-499. doi:10.1002/jcp.26605. https://pubmed.ncbi.nlm.nih.gov/29904924/
2. Liu, Danping, Wang, Xiaoping, Liu, Ying, Zhang, Zhen, Lv, Peng. 2022. Actin-Binding LIM 1 (ABLIM1) Inhibits Glioblastoma Progression and Serves as a Novel Prognostic Biomarker. In Disease markers, 2022, 9516808. doi:10.1155/2022/9516808. https://pubmed.ncbi.nlm.nih.gov/36583064/
3. Sibira, Rayan, Vu, Anna, Giubellino, Alessio, Murugan, Paari. 2024. Spitz melanoma with MAP3K8::ABLIM1 rearrangement: a case report with review of the literature. In Diagnostic pathology, 19, 133. doi:10.1186/s13000-024-01551-9. https://pubmed.ncbi.nlm.nih.gov/39363234/
4. Jin, Su Hyun, Kim, Hyunsoo, Gu, Dong Ryun, Choi, Yongwon, Lee, Seoung Hoon. . Actin-binding LIM protein 1 regulates receptor activator of NF-κB ligand-mediated osteoclast differentiation and motility. In BMB reports, 51, 356-361. doi:. https://pubmed.ncbi.nlm.nih.gov/29921413/
5. Ohsawa, Natsumi, Koebis, Michinori, Mitsuhashi, Hiroaki, Nishino, Ichizo, Ishiura, Shoichi. 2014. ABLIM1 splicing is abnormal in skeletal muscle of patients with DM1 and regulated by MBNL, CELF and PTBP1. In Genes to cells : devoted to molecular & cellular mechanisms, 20, 121-34. doi:10.1111/gtc.12201. https://pubmed.ncbi.nlm.nih.gov/25403273/